Literature DB >> 21331991

Relationship of increased serum brain natriuretic peptide levels with hepatic failure, portal hypertension and treatment in patients with cirrhosis.

Vural Taner Yilmaz1, Cenker Eken, Ali Berkant Avci, Adil Duman, Yaşar Tuna, Mete Akin, Bülent Yildirim.   

Abstract

BACKGROUND/AIMS: Brain natriuretic peptide is a cardiac neurohormone secreted from ventricles in response to end diastolic pressure and increased volume. It has diuretic, natriuretic and vasodilator effects. In cirrhosis, a hyperdynamic circulation occurs because of hemodynamic and hemostatic alterations. The increase in brain natriuretic peptide concentration shows parallelism with the stage of cirrhosis. The aim of this study is to investigate the relation of increased brain natriuretic peptide level with the pathophysiologic components of cirrhosis and treatment.
METHODS: Ninety-five cirrhotic patients in different stages (Child-A: 33; Child-B: 25; Child-C:37) and age and sex matched 86 healthy individuals were recruited for the study. Brain natriuretic peptide concentration was measured with brain natriuretic peptide-Triage test device using fluoresan immune assay method.
RESULTS: Brain natriuretic peptide levels of patients with hepatic cirrhosis were significantly higher compared to control group (288.5±329.2/60.2±29.5/p=0.000, respectively). Serum brain natriuretic peptide levels were positively correlated with Child score (Child A-B-C; 201.2±266/258.7±233.6/386.5±407.7, respectively). A negative correlation was observed between brain natriuretic peptide and albumin levels (p=0.002). Brain natriuretic peptide concentration was significantly correlated with the grade of esophagus varices, and presence of ascites and collateral circulation (p=0.006; p=0.001; p=0.002; respectively). Patients receiving with beta-blocker and diuretic treatments had significantly higher brain natriuretic peptide levels.
CONCLUSIONS: High brain natriuretic peptide levels in patients with cirrhosis may be due to hepatocellular insufficiency or portal hypertension, but a cardiomyopathy developing insiduously should not be regarded.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21331991     DOI: 10.4318/tjg.2010.0124

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  6 in total

1.  Characterization of uncommon portosystemic collateral circulations in patients with hepatic cirrhosis.

Authors:  Qin Wu; Lijun Shen; Jindong Chu; Xuemei Ma; Bo Jin; Fanping Meng; Jinpin Chen; Yanling Wang; Libing Wu; Jun Han; Wenhui Zhang; Wei Ma; Huaming Wang; Hanwei Li
Journal:  Oncol Lett       Date:  2014-10-22       Impact factor: 2.967

2.  Brain Natriuretic Peptide in Liver Cirrhosis and Fatty Liver: Correlation with Cardiac Performance.

Authors:  Amna Metwaly; Ashraf Abdel Khalik; Fatma Mohammad Nasr; Amal Ismail Sabry; Mohamed Fathy Gouda; Mona Hassan
Journal:  Electron Physician       Date:  2016-02-25

3.  Evaluation of cardiac functions of cirrhotic children using serum brain natriuretic peptide and tissue Doppler imaging.

Authors:  Aya M Fattouh; Mortada H El-Shabrawi; Enas H Mahmoud; Wafaa O Ahmed
Journal:  Ann Pediatr Cardiol       Date:  2016 Jan-Apr

4.  The heart matters when the liver shatters! Cirrhotic cardiomyopathy: frequency, comparison, and correlation with severity of disease.

Authors:  Iftikhar Haider Naqvi; Khalid Mahmood; Muhammad Naeem; Aneel Sham Vashwani; Syed Ziaullah
Journal:  Prz Gastroenterol       Date:  2016-02-16

5.  Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.

Authors:  Shao-Jung Hsu; Hui-Chun Huang; Chiao-Lin Chuang; Ching-Chih Chang; Ming-Chih Hou; Fa-Yauh Lee; Shou-Dong Lee
Journal:  Pharmaceutics       Date:  2020-04-02       Impact factor: 6.321

6.  Doppler myocardial performance index combined with plasma B-type natriuretic peptide levels as a marker of cardiac function in patients with decompensated cirrhosis.

Authors:  Li-Kun Wang; Xiao-Fei An; Xue-Liang Wu; Su-Mei Zhang; Rui-Min Yang; Chao Han; Jie-Lin Yang; Yi-Cheng Wang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.